{"address1": "675 Massachusetts Avenue", "address2": "14th Floor", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "857 242 1600", "website": "https://sperotherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ankit  Mahadevia M.D., MBA", "age": 43, "title": "Co-Founder & Director", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 1385907, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy  Keutzer", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 938570, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Esther P. Rajavelu", "age": 45, "title": "Interim President, Interim CEO, CFO, Chief Business Officer & Treasurer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James P. Brady", "title": "Chief Human Resource Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.72, "open": 0.68, "dayLow": 0.68, "dayHigh": 0.75, "regularMarketPreviousClose": 0.72, "regularMarketOpen": 0.68, "regularMarketDayLow": 0.68, "regularMarketDayHigh": 0.75, "payoutRatio": 0.0, "beta": 0.686, "forwardPE": -0.62522525, "volume": 178961, "regularMarketVolume": 178961, "averageVolume": 181771, "averageVolume10days": 172800, "averageDailyVolume10Day": 172800, "bid": 0.683, "ask": 0.7094, "bidSize": 1, "askSize": 1, "marketCap": 38795016, "fiftyTwoWeekLow": 0.68, "fiftyTwoWeekHigh": 1.8, "priceToSalesTrailing12Months": 0.80861694, "fiftyDayAverage": 0.8098, "twoHundredDayAverage": 1.13924, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -9796955, "profitMargins": -1.42914, "floatShares": 41896412, "sharesOutstanding": 55900600, "sharesShort": 437248, "sharesShortPriorMonth": 429588, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.008, "heldPercentInsiders": 0.23861, "heldPercentInstitutions": 0.24272, "shortRatio": 4.58, "shortPercentOfFloat": 0.0097, "impliedSharesOutstanding": 55900600, "bookValue": 0.845, "priceToBook": 0.82130176, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -68566000, "trailingEps": -1.27, "forwardEps": -1.11, "enterpriseToRevenue": -0.204, "enterpriseToEbitda": 0.135, "52WeekChange": -0.6122905, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.694, "targetHighPrice": 5.0, "targetLowPrice": 5.0, "targetMeanPrice": 5.0, "targetMedianPrice": 5.0, "recommendationMean": 2.66667, "recommendationKey": "hold", "numberOfAnalystOpinions": 2, "totalCash": 52889000, "totalCashPerShare": 0.946, "ebitda": -72482000, "totalDebt": 4297000, "quickRatio": 2.147, "currentRatio": 2.186, "totalRevenue": 47977000, "debtToEquity": 9.316, "revenuePerShare": 0.888, "returnOnAssets": -0.3093, "returnOnEquity": -0.89619005, "grossProfits": -48780000, "freeCashflow": -25126500, "operatingCashflow": -23444000, "revenueGrowth": -0.795, "grossMargins": -1.0167401, "ebitdaMargins": -1.51077, "operatingMargins": -1.3858, "financialCurrency": "USD", "symbol": "SPRO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Spero Therapeutics, Inc.", "longName": "Spero Therapeutics, Inc.", "regularMarketChange": -0.026000023, "regularMarketDayRange": "0.68 - 0.75", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 181771, "fiftyTwoWeekLowChange": 0.013999999, "fiftyTwoWeekLowChangePercent": 0.020588232, "fiftyTwoWeekRange": "0.68 - 1.8", "fiftyTwoWeekHighChange": -1.106, "fiftyTwoWeekHighChangePercent": -0.61444443, "fiftyTwoWeekChangePercent": -61.22905, "earningsTimestamp": 1743105660, "earningsTimestampStart": 1747133940, "earningsTimestampEnd": 1747656000, "earningsCallTimestampStart": 1743107400, "earningsCallTimestampEnd": 1743107400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.27, "epsForward": -1.11, "epsCurrentYear": -2.32, "priceEpsCurrentYear": -0.29913795, "fiftyDayAverageChange": -0.11580002, "fiftyDayAverageChangePercent": -0.1429983, "twoHundredDayAverageChange": -0.44524002, "twoHundredDayAverageChangePercent": -0.39082196, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.7 - Hold", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1509629400000, "regularMarketChangePercent": -3.6111143, "regularMarketPrice": 0.694, "corporateActions": [], "regularMarketTime": 1743537601, "exchange": "NMS", "messageBoardId": "finmb_240573619", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "displayName": "Spero Therapeutics", "trailingPegRatio": null}